ALK and non-small cell lung carcinoma: In the future, the ALTA-3 trial (NCT03596866) aims to assess how well brigatinib performs compared to alectinib in individuals with advanced ALK+ NSCLC resistant to crizotinib, offering additional information about the effectiveness and relative results of these therapies [92].